Pharmaceuticals, Biotechnology and Life Sciences
ADC Therapeutics, an oncology drug discovery and development company, has dosed first patient in its Phase Ib clinical trial of ADCT-301 in patients with selected solid tumors that are locally advanced or metastatic.
Basilea Pharmaceutica’s CEO David Veitch, will present at the 37th Annual J. P. Morgan Healthcare Conference on January 10, 2019, where he’ll describe both the progress made during 2018 and the priorities for 2019 to deliver on the key elements of Basilea’s strategy for continued value creation, the company said Friday.
ObsEva is evaluating long term administration of linzagolix in two dosing regimens with recruited patients for third phase of testing oral gonadotropin releasing hormone (GnRH) receptor antagonist Linzagolix.
In addition to yesterda’s announcement of moving to buy CAR-T cell producer CellforCure from LFB, Novartis today announced that it acquired another biopharmaceutical company focused on developing radioligand and CAR-T therapies for cancer treatment, the US based Endocyte, Inc.
GenomOncology, a technology solution provider for oncology, named Brad Wertz as the new Chairman and Chief Executive Officer (CEO), who’ll assume the position from the start of year 2019. Wertz has been a founding investor and chairman of the board since the beginning, and has increased his involvement as the company has grown over the past two years.
AstraZeneca and Merck’s work on Lynparza is looking at mroe financial return after the US Food and Drug Administration (FDA) approved it for for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer.
ValiRx journey of bringing closer to market its leading anti-cancer therapeutic VAL201 for patients with hormone-sensitive and hormone-resistant prostate cancer, took a…
Swiss Helsinn Group and Mundipharma China Pharmaceutical will now sell ALOXI IV in China, as it got approval from the…
A clinical stage biopharmaceutical company, 4D pharma, pioneering the development of Live Biotherapeutic Products, has made a deal with a subsidiary of…
Celgene Corporation’s study testing Revlimid on patients with previously untreated follicular lymphoma showed that treatment with a chemotherapy-free R2 regimen offered numerically…